Enzybiotics: New weapon in the army of antimicrobials: A review

Asian Journal of Animal and Veterinary Advances

Volumn 9, Issue 3, 2014, Pages 144-163

  Tiwari, Ruchi ^a   Dhama, Kuldeep ^b   Chakraborty, Sandip ^c   Kapoor, Sanjay ^d  

^a Uttar Pradesh Pandit Deen Dayal Upadhayay Pashu Chikitsa Vigyan Vishwavidyalay Evum Go Anusandhan Sansthan   (India)

^b INDIAN VETERINARY RESEARCH INSTITUTE   (India)

^c Department of Animal Resources Development ^*  (India)

^d LALA LAJPAT RAI UNIVERSITY OF VETERINARY AND ANIMAL SCIENCES   (India)

Author keywords

Animals; Antimicrobial; Bacterial infections; Bacteriophage; Endolysins; Human; Lysins; Resistant bacteria; Therapy

Indexed keywords

EID: 84899028180     PISSN: 16839919     EISSN: None     Source Type: Journal    
DOI: 10.3923/ajava.2014.144.163     Document Type: Article

References (142)

1. Ahluwalia, A.K. and B.S. Sekhon, 2012. Enzybiotics: A promising approach to fight infectious diseases and an upcoming need for future. J. Pharm. Educ. Res., 3: 42-51.
2. Amarpal, K. Dhama, S. Chakraborty, R. Tiwari and S. Nates an, 2013. Stem cells and their clinical/therapeutic applications in biomedical and veterinary science-the perspectives. Res. Opin. Anim. Vet. Sci., 3: 261-279.
3. Antachopoulos, C. and E. Roilides, 2005. Cytokines and fungal infections. Br. J. Haematol., 129: 583-596.
4. Becker, S.C., J. Foster-Frey and D.M. Donovan, 2008. The phage K lytic enzyme LysK and lysostaphin act synergistically to kill MRSA. FEMS Microbiol. Lett., 287: 185-191.
5. Borysowski, J. B. Weber-Dabrowska and A. Gorski, 2006. Bacteriophage endolysins as a novel class of antibacterial agents. Exp. Biol. Med., 231: 366-377.
6. Borysowski, J. and A. Gorski, 2010. Enzybiotics and their Potential Applications in Medicine. In: Enzybiotics: Antibiotic enzymes as Drugs and Therapeutics, Villa, T.G. and P. Veiga-Crespo (Eds.). John Wiley and Sons, New York, USA., pp: 1-26.
7. Breithaupt, H., 1999. The new antibiotics. Nat. Biotechnol., 17: 1165-1169.
8. Brussow, H., 2001. Phages of dairy bacteria. Annu. Rev. Microbiol., 55: 283-303.
9. Cascales, E., S.K. Buchanan, D. Duche, C. Kleanthous and R. Lloubes et al., 2007. Colicin biology. Microbiol. Mol. Biol. Rev., 71: 158-229.
10. Celia, L.K., D. Nelson and D.E. Kerr, 2008. Characterization of a bacteriophage lysin (Ply700) from Streptococcus uberis. Vet. Microbiol., 130: 107-117.
11. Cheng, Q., D. Nelson, S. Zhu and V.A. Fischetti, 2005. Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme. Antimicrob. Agents Chemother., 49: 111-117.
12. Clark, J.R. and J.B. March, 2006. Bacteriophages and biotechnology: Vaccines, gene therapy and antibacterials. Trends Biotechnol., 124: 212-218.
13. Climo, M.W., R.L. Patron, B.P. Goldstein and G.L. Archer, 1998. Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis. Antimicrob. Agents Chemother., 42: 1355-1360.
14. Cole, K., M.B. Farnell, A.M. Donoghue, N.J. Stern and E.A. Svetoch et al., 2006. Bacteriocins reduce Campylobacter colonization and alter gut morphology in Turkey poults. Poult. Sci., 85: 1570-1575.
15. Cotter, P.D., C. Hill and R.P. Ross, 2006. What's in a name? Class distinction for bacteriocins. Nat. Rev. Microbiol., Vol. 4
16. Cravotto, G., L. Boffa, L. Genzini and D. Garella, 2010. Phytotherapeutics: An evaluation of the potential of 1000 plants. J. Clin. Pharm. Therap., 35: 11-48.
17. Cruz-Chamorro, L., M.A. Puertollano, E. Puertollano, G.A. de Cienfuegos and M.A. de Pablo, 2006. In vitro biological activities of magainin alone or in combination with nisin. Peptides, 27: 1201-1209.
18. Da Silva, W.D. and D.Y. Tambourgi, 2010. IgY: A promising antibody for use in immunodiagnostic and in immunotherapy. Yet. Immunol. Immunopathol., 135: 173-180.
19. Dajcs, J.J., B.A. Thibodeaux, E.B.H. Hume, X. Zheng, G.D. Sloop ansd R.J. O'Callaghan, 2001. Lysostaphin is effective in treating methicillin-resistant Staphylococcus aureus endophthalmitis in the rabbit. Curr. Eye Res., 22: 451-457.
20. Dajcs, J.J., B.A. Thibodeaux, D.O. Girgis, M.D. Shaffer, S.M. Delvisco and R.J. O'Callaghan, 2002. Immunity to lysostaphin and its therapeutic value for ocular MRSA infections in the rabbit. Invest. Ophthalmol. Visual Sci., 43: 3712-3716.
21. De Groot, A.S. and D.W. Scott, 2007. Immunogenicity of protein therapeutics. Trends Immunol., 28: 482-490.
22. De Vries, J., K. Harms, I. Broer, G. Kriete, A. Mahn, K. During and W. Wackernagel, 1999. The bacteriolytic activity in transgenic potatoes expressing a chimeric T4 lysozyme gene and the effect of T4 lysozyme on soil- and phytopathogenic bacteria. Syst. Applied Microbiol., 22: 280-286.
23. Deb, R., A. Kumar, S. Chakraborty, A.K. Verma and R. Tiwari et al., 2013. Trends in diagnosis and control of bovine mastitis: A review. Pak. J. Biol. Sci., 16: 1653-1661.
24. Deutsch, S.M., S. Guezenec, M. Piot, S. Foster and S. Lortal, 2004. Mur-LH, Thebroad spectrum endolysin of Lactobacillus helveticus temperate bacteriophage f-0303. Applied Environ. Microbiol., 70: 96-103.
25. Dhama, K., R.S. Chauhan and L. Singhal, 2005. Anti-cancer activity of cow urine: Current status and future directions. Int. J. Cow Sci., 1: 1-25.
26. Dhama, K., M. Mahendran, S. Tomar and R.S. Chauhan, 2008. Beneficial effects of probiotics and prebiotics in livestock and poultry: The current perspectives. Intas Polivet, 9: 1-12.
27. Dhama, K., M.S. Basaraddi, R. Tiwari and L.R. Ananthakrshna, 2011. Egg Yolk Antibodies (EYA): Applications in poultry. Poult. Technol., 6: 20-24.
28. Dhama, K., R. Tiwari, S. Chakraborty, A. Kumar, M. Karikalan, R. Singh and R.B. Rai, 2013a. Global warming and emerging infectious diseases of animals and humans: Current scenario, challenges, solutions and future perspectives: A review. Int. J. Curr. Res., 5: 1942-1958.
29. Dhama, K., S. Chakraborty and R. Tiwari, 2013b. Panchgavya therapy (Cowpathy) in safeguarding health of animals and humans-a review. Res. Opin. Anim. Vet. Sci., 3: 170-178.
30. Dhama, K., S. Chakraborty, M.Y. Wani, R. Tiwari and R. Barathidasan, 2013c. Cytokine therapy for combating animal and human diseases: A review. Res. Opin. Anim. Vet. Sci., 3: 195-208.
31. Dhama, K., S. Chakraborty, Mahima, M.Y. Wani and A.K. Verma et al., 2013d. Novel and emerging therapies safeguarding health of humans and their companion animals: A review. Pak. J. Biol. Sci., 16: 101-111.
32. Dhama, K., S. Chakraborty, S. Kapoor, R. Tiwari and A. Kumar et al., 2013e. One world, one health-veterinary perspectives. Adv. Anim. Vet. Sci., 1: 5-13.
33. Diez-Gonzalez, F., 2007. Use of Bacteriocin in Livestock. In: Research and applications in bacteriocins, Riley, M.A. and O. Gillor (Eds.). Horizon Bioscience, Norfolk, UK., pp: 117-129.
34. Donovan, D.M., J. Foster-Frey, S. Dong, G.M. Rousseau, S. Moineau and D.G. Pritchard, 2006a. The cell lysis activity of the Streptococcus agalactiae bacteriophage B30 endolysin relies on the cysteine, histidine-dependent amidohydrolase/peptidase domain. Applied Environ. Microbiol., 72: 5108-5112.
35. Donovan, D.M., M. Lardeo and J. Foster-Frey, 2006b. Lysis of staphylococcal mastitis pathogens by bacteriophage phill endolysin. FEMS Microbiol. Lett., 265: 133-139.
36. Donovan, D.M., S. Dong, W. Garrett, G.M. Rousseau, S. Moineau and D.G. Pritchard, 2006c. Peptidoglycan hydrolase fusions maintain their parental specificities. Applied Environ. Microbiol., 72: 2988-2996.
37. Donovan, D.M., 2007. Bacteriophage and peptidoglycan degrading enzymes with antimicrobial applications. Recent Patents Biotechnol., 1: 113-122.
38. Fabricant, D.S. and N.R. Farnsworth, 2001. The value of plants used in traditional medicine for drug discovery. Environ. Health Perspect., 109: 69-75.
39. Farkas-Himsley, H., 1980. Bacteriocins-are they broad-spectrum antibiotics? J. Antimicrob. Chemother., 6: 424-426.
40. Fenton, M., P. Ross, O. McAuliffe, J. O'Mahony and A. Coffey, 2010. Recombinant bacteriophage lysins as antibacterials. Bioengineered Bugs, 1: 9-16.
41. Ferella, A., D. Bellido, P. Chacana, A. Wigdorovitz, M.J. Santos and M.V. Mozgovoj, 2012. Chicken egg yolk antibodies against bovine respiratory syncytial virus neutralize the virus in vitro. Proc. Vaccinol., 6: 33-38.
42. Fischetti, V.A., 2003. Novel method to control pathogenic bacteria on human mucous membranes. Ann. N. Y. Acad. Sci, 987: 207-214.
43. Fischetti, V.A., D. Nelson and R. Schuch, 2006. Reinventing phage therapy: Are the parts greater than the sum? Nat. Biotechnol, 12: 1508-1511.
44. Fischetti, V.A, 2010. Bacteriophage Lysins: Theultimate Enzybiotic. In: Enzybiotics: Antibiotic Enzymes as Drugs and Therapeutics, Villa, T.G. and P. Veiga-Crespo (Eds.). John Wiley and Sons Inc, New York, USA, pp: 107-122.
45. Gaeng, S, S. Scherer, H. Neve and M.J. Loessner, 2000. Gene cloning and expression and secretion of Listeria monocytogenes bacteriophage-lytic enzymes in Lactococcus lactis. Applied Environ. Microbiol, 66: 2951-2958.
46. Garcia, P, B. Martinez, L. Rodriguez and A. Rodriguez, 2010. Synergy between the phage endolysin LysH5 and nisin to kill Staphylococcus aureus in pasteurized milk. Int. J. Food Microbiol, 141: 151-155.
47. Ghabrial, S.A, 1980. Effects of fungal viruses on their hosts. Annu. Rev. Phytopathol, 18: 441-461.
48. Ghannad, M.S. and A. Mohammadi, 2012. Bacteriophage: Time to re-evaluate the potential of phage therapy as a promising agent to control multidrug-resistant bacteria. Iran. J. Basic Med. Sci, 15: 693-701.
49. Gil-Montoya, J.A, I. Guardia-Lopez and M.A. Gonzalez-Moles, 2008. Evaluation of the clinical efficacy of a mouthwash and oral gel containing the antimicrobial proteins lactoperoxidase, lysozyme and lactoferrin in elderly patients with dry mouth-a pilot study. Gerodontology, 25: 3-9.
50. Hankin, M.E., 1896. The bactericidal action of the waters of the Jumna and Ganges on the cholera vibrio. Ann. Inst. Pasteur., 10: 511-523.
51. Hanlon, G.W., 2007. Bacteriophages: An appraisal of their role in the treatment of bacterial infections. Int. J. Antimicrob. Agents, 30: 118-128.
52. Haq, I.U., W.N. Chaudhry, M.N. Akhtar, S. Andleeb and I. Qadri, 2012. Bacteriophages and their implications on future biotechnology: A review. Virol. J., Vol. 9 10.1186/1743-422X-9-9
53. Hashemi, S.R. and H. Davoodi, 2012. Herbal plants as new immuno-stimulator in poultry industry: A review. Asian J. Anim. Yet. Adv., 7: 105-116.
54. Hawari, A.D. and F. Al-Dabbas, 2008. Prevalence and distribution of mastitis pathogens and their resistance against antimicrobial agents in dairy cows in Jordan. Am. J. Anim. Vet. Sci., 3: 36-39.
55. Helal, R., G. Bader and M.F. Melzig, 2012. Stimulation of lysozyme release by selected microbial preparations. Die Pharmazie Int. J. Pharm. Sci., 67: 564-566.
56. Hermoso, J.A., J.L. Garcia and P. Garcia, 2007. Taking aim on bacterial pathogens: From phage therapy to enzybiotics. Curr. Opin. Microbiol., 10: 461-472.
57. Hojckova, K., M. Stano and L. KLucar, 2013. phiBIOTICS: Catalogue of therapeutic enzybiotics, relevant research studies and practical applications. BMC Microbiol., Vol. 13 10.1186/1471-2180-13-53
58. Hoq, M.I., K. Mitsuno, Y. Tsujino, T. Aoki and H.R. Ibrahim, 2008. Triclosan-lysozyme complex as novel antimicrobial macromolecule: A new potential of lysozyme as phenolic drug-targeting molecule. Int. J. Biol. Macromol., 42: 468-477.
59. Jazayeri, J.A. and G.J. Carroll, 2008. Fc-based cytokines: Prospects for engineering superior therapeutics. BioDrugs, 22: 11-26.
60. Joerger, R.D., 2003. Alternatives to antibiotics: Bacteriocins, antimicrobial peptides and bacteriophages. Poult. Sci., 82: 640-647.
61. Kanamaru, S., Y. Ishiwata, T. Suzuki, M.G. Rossmann and F. Arisaka, 2005. Control of bacteriophage T4 tail lysozyme activity during the infection process. J. Mol. Biol., 346: 1013-1020.
62. Kerr, D.E., K. Plaut, A.J. Bramley, C.M. Williamson and A.J. Lax et al., 2001. Lysostaphin expression in mammary glands confers protection against staphylococcal infection in transgenic mice. Nat. Biotechnol., 19: 66-70.
63. Kohler, P.L., H.L. Hamilton, K. Cloud-Hansen and J.P. Dillard, 2007. AtlA functions as a peptidoglycan lytic transglycosylase in the Neisseria gonorrhoeae type IV secretion system. J. Bacteriol., 189: 5421-5428.
64. Kokai-Kun, J.F., S.M. Walsh, T. Chanturiya and J.J. Mond, 2003. Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model. Antimicrob. Agents Chemother., 47: 1589-1597.
65. Kokai-Kun, J.F., T. Chanturiya and J.J. Mond, 2007. Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model. J. Antimicrob. Chemother., 60: 1051-1059.
66. Koonin, E.V., 2012. The wonder world of microbial viruses. Expert Rev. Anti-Infective Therapy, 8: 1097-1099.
67. Korndorfer, I.P., J. Danzer, M. Schmelcher, M. Zimmer, A. Skerra and M.J. Loessner, 2006. The crystal structure of the bacteriophage PSA endolysin reveals a unique fold responsible for specific recognition of Listeria cell walls. J. Mol. Biol., 364: 678-689.
68. Kretzer, J.W., R. Lehmann, M. Schmelcher, M. Banz, K.P. Kim, C. Korn and M.J. Loessner, 2007. Use of high-affinity cell wall-binding domains of bacteriophage endolysins for immobilization and separation of bacterial cells. Applied Environ. Microbiol., 73: 1992-2000.
69. Kusuma, C, A. Jadanova, T. Chanturiya and J.F. Kokai-Kun, 2007. Lysostaphin-resistant variants of Staphylococcus aureus demonstrate reduced fitness in vitro and in vivo. Antimicrob. Agents Chemother, 51: 475-482.
70. Line, J.E, E.A. Svetoch, B.Y. Eruslanov, Y.Y. Perelygin and E.Y. Mitsevich et al., 2008. Isolation and purification of enterocin E-760 with broad antimicrobial activity against gram-positive and gram-negative bacteria. Antimicrob. Agents Chemother, 52: 1094-1100.
71. Loeffler, J.M, D. Nelson and V.A. Fischetti, 2001. Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science, 294: 2170-2172.
72. Loessner, M.J, A. Schneider and S. Scherer, 1995. A new procedure for efficient recovery of DNA, RNA and proteins from Listeria cells by rapid lysis with a recombinant bacteriophage endolysin. Applied Environ. Microbiol, 61: 1150-1152.
73. Loessner, M.J, S.K. Maier, H. Daubek-Puza, G. Wendlinger and S. Scherer, 1997. Three Bacillus cereus bacteriophage endolysins are unrelated but reveal high homology to cell wall hydrolases from different bacilli. J. Bacteriol, 179: 2845-2851.
74. Loessner, M.J, S. Gaeng, G. Wendlinger, S.K. Maier and S. Scherer, 1998. The two-component lysis system of Staphylococcus aureus bacteriophage Twort: A large TTG-start holin and an associated amidase endolysin. FEMS Microbiol. Lett, 162: 265-274.
75. Loessner, M.J, S. Gaeng and S. Scherer, 1999. Evidence for a Holm-like protein gene fully embedded out of frame in the endolysin gene of Staphylococcus aureus bacteriophage 187. J. Bacteriol, 181: 4452-4460.
76. Loessner, M.J, K. Kramer, F. Ebel and S. Scherer, 2002. C-terminal domains of Listeria monocytogenes bacteriophage murein hydrolases determine specific recognition and High-affinity binding to bacterial cell wall carbohydrates. Mol. Microbiol, 44: 335-349.
77. Loessner, M.J, 2005. Bacteriophage endolysins-current state of research and applications. Curr. Opin. Microbiol, 8: 480-487.
78. Lopez, R, E. Garcia and P. Garcia, 2004. Enzymes for Anti-infective therapy: Phage lysins. Drug Discovery Today: Therapeutic Strategies, 1: 469-474.
79. Low, L.Y, C. Yang, M. Perego, A. Osterman and R.C. Liddington, 2005. Structure and lytic activity of a Bacillus anthracis prophage endolysin. J. Biol. Chem, 280: 35433-35439.
80. Low, L.Y, C. Yang, M. Perego, A. Osterman and R. Liddington, 2011. Role of net charge on catalytic domain and influence of cell wall binding domain on bactericidal activity, specificity and host range of phage lysins. J. Biol. Chem, 286: 34391-34403.
81. Mahima, A. Rahal, R. Deb, S.K. Latheef and H.A. Samad et al., 2012. Immunomodulatory and therauptic potential of herbal, traditional/indigenous and ethanoveterinary medicine. Pak. J. Biol. Sci, 15: 754-774.
82. Mahima, A.K. Verma, R. Tiwari, K. Karthik, S. Chakraborty, R. Deb and K. Dhama, 2013a. Nutraceuticals from fruits and vegetables at a glance: A review. J. Biol. Sci, 13: 38-47.
83. Mahima, A.M. Ingle, A.K. Verma, R. Tiwari and K. Karthik et al., 2013b. Immunomodulators in day to day life: A review. Pak. J. Biol. Sci, 16: 826-843.
84. Manoharadas, S, A. Witte and U. Blasi, 2009. Antimicrobial activity of a chimeric enzybiotic towards Staphylococcus aureus. J. Biotechnol, 139: 118-123.
85. Michael, A, S. Meenatchisundaram, G. Parameswari, T. Subbraj, R. Selvakumaran and S. Ramalingam, 2010. Chicken egg yolk antibodies (IgY) as an alternative to mammalian antibodies. Indian J. Sci. Technol, 3: 468-474.
86. Moak, M. and I.J. Molineux, 2004. Peptidoglycan hydrolytic activities associated with bacteriophage virions. Mol. Microbiol, 51: 1169-1183.
87. Mullan, W. M. A., 2003. Bacteriophage lysins. http://www.dairyscience.info/bacteriophage-lysins.html.
88. Navarre, W.W., H. Ton-That, K.F. Faull and O. Schneewind, 1999. Multiple enzymatic activities of the murein hydrolase from staphylococcal phage f 11. Identification of a D-alanyl-glycine endopeptidase activity. J. Biol. Chem., 274: 15847-15856.
89. Nelson, D., L. Loomis and Y.A. Fischetti, 2001. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc. Natl. Acad. Sci, 98: 4107-4112.
90. Nelson, D, R. Schuch, P. Chahales, S. Zhu and Y.A. Fischetti, 2006. PlyC: A multimeric bacteriophage lysin. Proc. Natl. Acad. Sci, 103: 10765-10770.
91. Nelson, D.C, M. Schmelcher, L. Rodriguez-Rubio, J. Klumpp, D.G. Pritchard, S. Dong and D.M. Donovan, 2012. Endolysins as antimicrobials. Adv. Virus Res, 83: 299-365.
92. Nicholls, E.F, L. Madera and R.E.W. Hancock, 2010. Immunomodulators as adjuvants for vaccines and antimicrobial therapy. Ann. N. Y. Acad. Sci, 1213: 46-61.
93. O'Flaherty, S, A. Coffey, W. Meaney, G.F. Fitzgerald and R.P. Ross, 2005. The recombinant phage lysin LysK has a broad spectrum of lytic activity against clinically relevant staphylococci, including Methicillin-resistant Staphylococcus aureus. J. Bacteriol, 187: 7161-7164.
94. Okeke, I.N, K.P. Klugman, Z.A. Bhutta, A.G. Duse and P. Jenkins et al., 2005. Antimicrobial resistance in developing countries. Part II: Strategies for containment. Lancet Infect. Dis, 5: 568-580.
95. Oluola, O, L. Kong, M. Fein and L.E. Weisman, 2007. Lysostaphin in treatment of neonatal Staphylococcus aureus infection. Antimicrobial Agents Chemother, 51: 2198-2200.
96. Patron, R.L, M.W. Climo, B.P. Goldstein and G.L. Archer, 1999. Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibility to vancomycin. Antimicrob. Agents Chemother, 43: 1754-1755.
97. Porter, C.J, R. Schuch, A.J. Pelzek, A.M. Buckle and S. McGowan et al., 2007. The 1.6 A crystal structure of the catalytic domain of PlyB, a bacteriophage lysin active against Bacillus anthracis. J. Mol. Biol, 366: 540-550.
98. Pritchard, D.G, S. Dong, J.R. Baker and J.A. Engler, 2004. The bifunctional peptidoglycan lysin of Streptococcus agalactiae bacteriophage B30. Microbiology, 150: 2079-2087.
99. Qin, Z, Y. Ou, L. Yang, Y. Zhu, T. Tolker-Nielsen, S. Molin and D. Qu, 2007. Role of Autolysin-mediated DNA release in biofilm formation of Staphylococcus epidermidis. Microbiology, 153: 2083-2092.
100. Rahimi, S, E. Salehifar, S.A. Ghorashi, J.L. Grimes and M.A.K. Torshizi, 2007. The effect of egg-derived antibody on prevention of avian influenza subtype H9N2 in layer chicken. Int. J. Poult. Sci, 6: 207-210.
101. Rashel, M, J. Uchiyama, T. Ujihara, Y. Uehara and S. Kuramoto et al., 2007. Efficient elimination of Multidrug-resistant Staphylococcus aureus by cloned lysin derived from bacteriophage phi MR11. J. Infect. Dis, 196: 1237-1247.
102. Sand, S.L, T.M. Haug, J. Nissen-Meyer and O. Sand, 2007. The bacterial peptide pheromone plantaricin A permeabilizes cancerous, but not normal, rat pituitary cells and differentiates between the outer and inner membrane leaflet. J. Membrane Biol, 216: 61-71.
103. San deep, K, 2006. Bacteriophage precision drug against bacterial infections. Curr. Sci, 90: 631-633.
104. Sass, P. and G. Bierbaum, 2007. Lytic activity of recombinant bacteriophage f 11 and f 12 endolysins on whole cells and biofilms of Staphylococcus aureus. Applied Environ. Microbiol, 73: 347-352.
105. Sava, G, 1996. Pharmacological aspects and therapeutic applications of lysozymes. EXS, 75: 433-449.
106. Schmelcher, M, D.M. Donovan and M.J. Loessner, 2012. Bacteriophage endolysins as novel antimicrobials. Future Microbiol, 7: 1147-1171.
107. Scholl, D, S. Rogers, S. Adhya and C.R. Merril, 2001. Bacteriophage Kl-5 encodes two different tail fiber proteins, allowing it to infect and replicate on both K1 and K5 strains of Escherichia coli. J. Virol, 75: 2509-2515.
108. Schuch, R, D. Nelson and V.A. Fischetti, 2002. A bacteriolytic agent that detects and kills Bacillus anthracis. Nature, 418: 884-889.
109. Seal, B.S, 2013. Characterization of bacteriophages virulent for Clostridium perfringens and identification of phage lytic enzymes as alternatives to antibiotics for potential control of the bacterium. Poult. Sci, 91: 526-533.
110. Shah, A, J. Mond and S. Walsh, 2004. Lysostaphin-coated catheters eradicate Staphylococccus aureus challenge and block surface colonization. Antimicrobial Agents Chemother, 48: 2704-2707.
111. Shinde, P. L. and B. J. Chae, 2009. Antimicrobial peptides as an alternative to antibiotics in pigs nutrition. Nutrition, October 20, 2009. http://www.pig333.com/ nutrition/antimicrobial-peptides-as-an-alternative-to-antibiotics-in-pigs-nutrit_1917/.
112. Shuren, J, 2006. Food additives permitted for direct addition to food for human consumption: Bacteriophage preparation. Federal Register/Vol. 71, No. 160/August 18, 2006/Rules and Regulations, Office of the Federal Register, National Archives and Records Administration, Washington, DC, USA, pp: 47729-47732.
113. Skurnik, M. and E. Strauch, 2006. Phage therapy: Facts and fiction. Int. J. Med. Miccrobiol, 296: 5-14.
114. Smith, T.J, S.A. Blackman and S.J. Foster, 2000. Autolysins of Bacillus subtilis: multiple enzymes with multiple functions. Microbiology, 146: 249-262.
115. Sourav, S, A. Patricia, S. Sharma, R. Kanungo, S. Jayachandran and K. Prashanth, 2010. Detection of pneumolysin and autolysin genes among antibiotic resistant Streptococcus pneumonia in invasive infections. Indian J. Med. Microbiol, 28: 34-39.
116. Sugahara, K, K.J. Yokoi, Y. Nakamura, T. Nishino, A. Yamakawa, A. Taketo and K. Kodaira, 2007. Mutational and biochemical analyses of the endolysin LysgaY encoded by the Lactobacillus gasseri JCM 113IT phage phi gaY. Gene, 404: 41-52.
117. Takac, M, A. Witte and U. Blasi, 2005. Functional analysis of the lysis genes of Staphylococcus aureus phage P68 in Escherichia coli. Microbiology, 151: 2331-2342.
118. Tenovuo, J.O, 2002. Clinical applications of antimicrobial host proteins lactoperoxidase, lysozyme and lactoferrin in xerostomia: Efficacy and safety. Oral Dis, 8: 23-29.
119. Tiwari, R, K. Dhama, M.Y. Wani, V. Verma, R.K. Vaid and R.S. Chauhan, 2011. Bacteriophage therapy: A novel tool for combating bacterial diseases of poultry-A review. J. Immunol. Immunopathol, 13: 55-66.
120. Tiwari, R, S.D. Hirpurkar and K. Dhama, 2012. Therapeutic Potential of Bacteriophages against Pathogenic Bacteria. LAP LAMBERT Academic Publishing, Germany, pp: 1-108.
121. Tiwari, R, S. Chakraborty and K. Dhama, 2013a. Miracle of herbs in antibiotic resistant wounds and skin infections: Treasure of nature-a review/ perspective. Pharma Sci. Monitor, 4: 214-248.
122. Tiwari, R, S. Chakraborty, K. Dhama, S. Rajagunalan and S.Y. Singh, 2013b. Antibiotic resistance-an emerging health problem: Causes, worries, challenges and solutions: A review. Int. J. Curr. Res, 5: 1880-1892.
123. Tiwari, R, K. Dhama, S. Chakraborty, A. Kumar, A. Rahal and S. Kapoor, 2014a. Bacteriophage therapy for safeguarding animal and human health: A review. Pak. J. Biol. Sci, 17: 301-315.
124. Tiwari, R, S. Chakraborty, K. Dhama, M.Y. Wani, A. Kumar and S. Kapoor, 2014b. Wonder world of phages: Potential biocontrol agents safeguarding biosphere and health of animals and humans-current scenario and perspectives. Pak. J. Biol. Sci, 17: 316-328.
125. Turner, M.S., F. Waldherr, M.J. Loessner and P.M. Giffard, 2007. Antimicrobial activity of lysostaphin and a Listeria monocytogenes bacteriophage endolysin produced and secreted by lactic acid bacteria. Syst. Applied Microbiol, 30: 58-67.
126. Turner, M.S., L.M. Hafner, T. Walsh and P.M. Giffard, 2004. Identification, characterisation and specificity of a cell wall lytic enzyme from Lactobacillus fermentum BR11. FEMS Microbiol. Lett, 238: 9-15.
127. Twort, F.W, 1915. An investigation on the nature of ultra-microscopic viruses. Lancet, 186: 1241-1243.
128. Wall, R.J, A.M. Powell, M.J. Paape, D.E. Kerr and D.D. Bannerman et al., 2005. Genetically enhanced cows resist intramammary Staphylococcus aureus infection. Nat. Biotechnol, 23: 445-451.
129. Wang, I.N, D.L. Smith and R. Young, 2000. Holins: The protein clocks of bacterial infection. Ann. Rev. Microbiol, 54: 799-825.
130. Wang, J, E.S. Wong, J.C. Whitley, J. Li and J.M. Stringer et al., 2011. Ancient antimicrobial peptides kill antibiotic-resistant pathogens: Australian mammals provide new options. PLoS One, Vol. 6. 10.1371/journal.pone.0024030
131. Wittmann, J, R. Eichenlaub and B. Dreiseikelmann, 2010. The endolysins of bacteriophages CMP1 and CN77 are specific for the lysis of Clavibacter michiganensis strains. Microbiology, 156: 2366-2373.
132. Wu, H, H. Lu, J. Huang, G. Li and Q. Huang, 2012. EnzyBase: A novel database for enzybiotic studies. BMC Microbiol, Vol. 12. 10.1186/1471-2180-12-54
133. Xie, J, R. Zhang, C. Shang and Y. Guo, 2009. Isolation and characterization of a bacteriocin produced by an isolated Bacillus subtilis LFB112 that exhibits antimicrobial activity against domestic animal pathogens. Afr. J. Biotechnol, 8: 5611-5619.
134. Xin, W, B.J. Wilkinson and R.K. Jayaswal, 1991. Sequence analysis of a Staphylococcus aureus gene encoding a peptidoglycan hydrolase activity. Gene, 102: 105-109.
135. Xu, M, D.K. Struck, J. Deaton, N. Wang and R. Young, 2004. A signal-arrest-release sequence mediates export and control of the phage PI endolysin. Proc. Natl. Acad. Sci. USA, 101: 6415-6420.
136. Yegani, M. and D.R. Korver, 2007. Application of egg yolk antibodies as replacement for antibiotics in poultry. World Poul, 23: 22-25.
137. Yokoi, K.J, N. Kawahigashi, M. Uchida, K. Sugahara and M. Shinohara et al., 2005. The two-component cell lysis genes holWMY and lysWMY of the Staphylococcus warneri M phage FWMY: Cloning, sequencing, expression and mutational analysis in Escherichia coli. Gene, 351: 97-108.
138. Yoong, P., R. Schuch, D. Nelson and Y.A. Fischetti, 2004. Identification of a broadly active phage lytic enzyme with lethal activity against Antibiotic-resistant Enterococcus faecalis and Enterococcus faecium. J. Bacteriol., 186: 4808-4812.
139. Young, R., 1992. Bacteriophage lysis: Mechanism and regulation. Microbiol. Rev., 56: 430-481.
140. Young, R. and U. Blasi, 1995. Holins: Form and function in bacteriophage lysis. FEMS Microbiol. Rev, 17: 195-205.
141. Zimmer, M, N. Yukov, S. Scherer and M.J. Loessner, 2002. The murein hydrolase of the bacteriophage f3626 dual lysis system is active against all tested Clostridium perfringens strains. Appl. Environ. Microbiol, 68: 5311-5317.
142. Zoll, S, B. Patzold, M. Schlag, F. Gotz, H. Kalbacher and T. Stehle, 2010. Structural basis of cell wall cleavage by a staphylococcal autolysin. PloS Pathog, Vol. 6.10.1371/journal.ppat.l000807.